• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields

    7/15/24 2:08:21 PM ET
    $CVS
    $MDT
    $PFE
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CVS alert in real time by email

    During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

    Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

    Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

    Pfizer Inc. (NYSE:PFE)

    • Dividend Yield: 5.81%
    • Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on July 10. This analyst has an accuracy rate of 70%.
    • BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and raised the price target from $33 to $36 on May 2. This analyst has an accuracy rate of 70%.
    • Recent News: On July 11, Pfizer announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.
    • Benzinga Pro's real-time newsfeed alerted to latest Pfizer's news

    CVS Health Corporation (NYSE:CVS)

    • Dividend Yield: 4.51%
    • Argus Research analyst Chris Graja maintained a Buy rating and cut the price target from $100 to $80 on May 8. This analyst has an accuracy rate of 70%.
    • Truist Securities analyst David Macdonald reiterated a Buy rating and lowered the price target from $90 to $66 on May 2. This analyst has an accuracy rate of 71%.
    • Recent News: CVS Health said it will report second-quarter financial results on Wednesday, Aug. 7.
    • Benzinga Pro's charting tool helped identify the trend in CVS stock.

    Medtronic plc (NYSE:MDT)

    • Dividend Yield: 3.59%
    • Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and raised the price target from $102 to $105 on May 24. This analyst has an accuracy rate of 73%.
    • Mizuho analyst Anthony Petrone maintained a Buy rating and increased the price target from $95 to $98 on Feb. 21. This analyst has an accuracy rate of 65%.
    • Recent News: On June 26, Medtronic announced the resignation of EVP and CFO Karen Parkhill.
    • Benzinga Pro's signals feature notified of a potential breakout in Medtronic's shares.

    Read More:

    • How To Earn $500 A Month From Bank of America Stock Ahead Of Q2 Earnings
    Get the next $CVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVS
    $MDT
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Medtronic plc.
    $MDT
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    CVS Health Corporation
    $CVS
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    CVS Health Corporation
    $CVS
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    CVS Health Corporation
    $CVS
    1/30/2025Hold → Buy
    Edward Jones
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    CVS Health Corporation
    $CVS
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    CVS Health Corporation
    $CVS
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $CVS
    $MDT
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc.

      6/4/25 2:36:00 PM ET
      $BFLY
      $MDT
      $ORCL
      $RXRX
      Medical Electronics
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Computer Software: Prepackaged Software
    • INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

      PHILADELPHIA, June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE:PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.  Shareholders of PFIZER may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) 875-3015 or visit: https://investigations.bergerm

      6/3/25 5:49:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

      6/2/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVS
    $MDT
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medtronic upgraded by Citigroup with a new price target

      Citigroup upgraded Medtronic from Neutral to Buy and set a new price target of $107.00 from $92.00 previously

      3/4/25 7:37:34 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CVS Health upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously

      2/13/25 7:04:02 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    $MDT
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Financial Officer Newman Brian was granted 21,861 shares (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      6/3/25 4:35:13 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, Chief Medical Officer Compton-Phillips Amy was granted 53,091 shares (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      6/3/25 4:33:21 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Chairman & CEO Bourla Albert

      4 - PFIZER INC (0000078003) (Issuer)

      6/3/25 11:44:01 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVS
    $MDT
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

      4 - CVS HEALTH Corp (0000064803) (Issuer)

      2/19/25 12:35:35 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVS
    $MDT
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVS
    $MDT
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CVS Health Corporation

      SC 13G - CVS HEALTH Corp (0000064803) (Subject)

      11/13/24 1:00:57 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

      SC 13G/A - Medtronic plc (0001613103) (Subject)

      2/13/24 5:09:43 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

      SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

      2/13/24 5:02:40 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    $MDT
    $PFE
    SEC Filings

    See more
    • SEC Form SD filed by Pfizer Inc.

      SD - PFIZER INC (0000078003) (Filer)

      5/30/25 1:07:24 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Medtronic plc.

      SD - Medtronic plc (0001613103) (Filer)

      5/28/25 5:30:45 PM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Medtronic plc (0001613103) (Filer)

      5/21/25 6:47:23 AM ET
      $MDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CVS
    $MDT
    $PFE
    Financials

    Live finance-specific insights

    See more
    • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

      6/2/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

      AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.) Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary with subsidiaries of A

      5/8/25 4:47:00 PM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $CVS
    $MDT
    $PFE
    Leadership Updates

    Live Leadership Updates

    See more
    • CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

      WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

      4/8/25 6:30:00 AM ET
      $CVS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations